Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis: early-phase trial registry
120 of 317 indexed Multiple Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #24 of 28,707 conditions by registered trial count.
317 US clinical trials · 120 currently recruiting · #24 of 28,707 conditions by registered trial count
Multiple Sclerosis: 317 US clinical trials tracked, 120 recruiting.
Multiple Sclerosis is the subject of 317 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 41 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 13 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis
OPEN 120 | RECR 38% | LATE 41 | EARLY 74 | RANK #24 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Myeloma (38% recruiting · 441 trials)
Multiple Sclerosis lists 120 open slots (38% of 317 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis recruits in line with its size-band peers.
120 of 317 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Sclerosis trials is spread across many organizations.
Biogen accounts for 13 of 317 trials (4.1%). 142 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Sclerosis enrolment sits around 61 participants.
Median target enrolment is 61 among the 316 trials that report a genuine target (sentinel values excluded). 181 of those (57.3%) plan for fewer than 100 participants.
-
Multiple Sclerosis research is mostly interventional.
231 interventional and 86 observational studies make up this index (72.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
317 total, page 1 of 7
NARCOMS Registry: A Multiple Sclerosis Registry
University of Texas Southwestern Medical Center
NCT01018537
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
Accelerated Cure Project for Multiple Sclerosis
NCT02486562
Longitudinal Cognitive Assessment by BoCA
Alzheimer's Light
NCT04114994
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
University of Pittsburgh
NCT02994121
Clinical Applications of Advanced Ophthalmic Imaging
University of Miami
NCT03135327
Genes and Environment in Multiple Sclerosis
Columbia University
NCT01353547
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001248
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00794352
Multiple Sclerosis Implementation Network (Registry)
The University of Texas Health Science Center, Houston
NCT07415824
Retinal Imaging in Neurodegenerative Disease
Duke University
NCT03233646
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
Accelerated Cure Project for Multiple Sclerosis
NCT06441617
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sanofi
NCT06141473
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Bristol-Myers Squibb
NCT05170126
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Biogen
NCT05688436
Identifying and Characterizing Preclinical MS
Yale University
NCT05787795
Complementary and Alternative Care in Multiple Sclerosis
Bastyr University
NCT01703429
MS-ResearchBiomarkerS
Cedars-Sinai Medical Center
NCT05204459
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Biogen
NCT05658497
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sanofi
NCT06141486
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Novartis Pharmaceuticals
NCT04933552
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis
Beth Israel Deaconess Medical Center
NCT04603196
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
TG Therapeutics
NCT06433765
Kesimpta (Ofatumumab) Pregnancy Registry
Novartis Pharmaceuticals
NCT05634967
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
TG Therapeutics
NCT06433752
Autoimmune Intervention Mastery Course Study
Terry L. Wahls
NCT05057676
Care in Multiple Sclerosis (MS)
NYU Langone Health
NCT07011914
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
NCT03816345
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
University of California, San Francisco
NCT07222618
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
TScan Therapeutics
NCT06587828
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
University of Illinois at Chicago
NCT04518657
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03109288
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
Brigham and Women's Hospital
NCT02649985
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
University of California, San Francisco
NCT06940323
Pathological Basis of MRI Signal Changes in Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)
NCT02659956
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Eli Lilly and Company
NCT06220669
Remote Therapeutic Monitoring Exercise Tracking
Shirley Ryan AbilityLab
NCT06306768
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Hoffmann-La Roche
NCT07074886
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
ModernaTX
NCT06735248
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
NYU Langone Health
NCT06901687
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
Tiffany J. Braley, MD, MS
NCT05269628
AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
University of Alabama at Birmingham
NCT04721717
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
NCT07325292
High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
Marquette University
NCT05735691
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
Mayo Clinic
NCT06788886
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
University of Illinois at Chicago
NCT05051618
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
Emory University
NCT06495138
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
Hoffmann-La Roche
NCT05704361
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
Universiteit Leiden
NCT07225868
HOBSCOTCH-MS-Efficacy Trial
Dartmouth-Hitchcock Medical Center
NCT06951919
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05285891
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 33 |
| Phase 3 | 24 |
| Phase 4 | 17 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis page
317 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 120 Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis condition card totals 317 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.